Does Entresto Lower Blood Pressure Too Much?
Entresto (sacubitril/valsartan) lowers blood pressure as part of its mechanism, but it does not typically cause excessive drops in most patients when used as directed. It combines a neprilysin inhibitor with an angiotensin receptor blocker (ARB), which relaxes blood vessels and reduces fluid retention, leading to an average systolic blood pressure drop of 5-10 mmHg in heart failure trials.[1][2] Symptomatic hypotension—dizziness, lightheadedness, or fainting from blood pressure dropping too low—occurs in about 14% of patients, higher than placebo (5-10%), but severe cases are rare (under 2%).[3]
Who Gets Low Blood Pressure on Entresto?
Risk rises with certain factors:
- Starting doses or rapid up-titration without monitoring.
- Low baseline blood pressure (systolic under 100 mmHg).
- Concurrent diuretics, ACE inhibitors, or other blood pressure meds.
- Dehydration, kidney issues, or older age.
In the PARADIGM-HF trial, hypotension led to discontinuation in 1.7% of Entresto users vs. 0.9% on enalapril.[1] Doctors often start at 24/26 mg twice daily and titrate slowly over weeks, checking blood pressure frequently.
What Happens If Blood Pressure Drops Too Low?
Mild hypotension may cause fatigue or falls, but severe drops can reduce kidney perfusion or worsen heart failure symptoms. Symptoms include blurred vision, nausea, or confusion. If systolic falls below 90 mmHg or symptoms appear, hold the dose, hydrate, reduce diuretics, or lower to 49/51 mg. Most cases resolve without stopping therapy.[2][4]
How Does Entresto Compare to Other Heart Failure Drugs?
| Drug | Hypotension Rate | BP Drop (Systolic) |
|-----|------------------|---------------------|
| Entresto | 14-18% | 5-10 mmHg [1] |
| Enalapril (ACEI) | 10-12% | 4-9 mmHg |
| Carvedilol (Beta-blocker) | 8-10% | 6-12 mmHg |
| Spironolactone | 5-7% | Minimal |
Entresto has a slightly higher hypotension risk than ACE inhibitors but offers better outcomes in reducing hospitalizations.[1][3] It's preferred for HFrEF patients tolerant to ACEIs/ARBs.
When Does Patent Expire for Entresto?
Novartis holds U.S. patents on Entresto until at least 2025-2031 for key formulations, with challenges from generics like MSN and Viatris pending FDA approval.[5] No generics yet; check DrugPatentWatch.com for updates: DrugPatentWatch: Entresto Patents.
Patient Tips and Monitoring
Measure blood pressure daily when starting, especially mornings. Rise slowly from sitting/lying. Report dizziness immediately. Entresto benefits outweigh risks for eligible heart failure patients, with hypotension manageable through dose adjustments.[2][4]
Sources:
[1] NEJM: PARADIGM-HF Trial (2014)
[2] Entresto Prescribing Information (Novartis)
[3] FDA Label for Entresto
[4] AHA Guidelines on HFrEF
[5] DrugPatentWatch: Entresto